Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 123144 results found since Jan 2013.
Translated article Implementation of the standardized process of drug therapy evaluation in inpatients and outpatients
CONCLUSIONS: This study shows a clinical pharmacist developed tool called SPEP that increased the pharmacist evaluation and pharmacist interventions number in multiple clinical scenarios. These were significant only in critical care patients. Future investigations should make effort to evaluate the quality and clinical impact of these interventions.PMID:37735005 | DOI:10.1016/j.farma.2023.06.003
Source: Farmacia Hospitalaria - September 21, 2023 Category: Drugs & Pharmacology Authors: A Gonz ález W Guti érrez T Fuenzalida F Lizana M Guti érrez N Severino Source Type: research
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:37735004 | DOI:10.1016/j.farma.2023.08.006
Source: Farmacia Hospitalaria - September 21, 2023 Category: Drugs & Pharmacology Authors: Ganfornina Andrades Ana F énix Caballero Silvia Salguero Olid Alba Alegre Del-Rey Emilio Jes ús Source Type: research
Hyperoside attenuates pyrrolizidine alkaloids-induced liver injury by ameliorating TFEB-mediated mitochondrial dysfunction
In conclusion, Hyp can activate the TFEB-mediated autophagy-lysosomal pathway and mitochondrial biogenesis through inhibition of mTORC1 activity, alleviating the liver injury induced by PAs, thus suggesting the potential value of Hyp in the treatment of PA-induced hepatotoxicity.PMID:37733287 | DOI:10.1007/s12272-023-01460-3
Source: Archives of Pharmacal Research - September 21, 2023 Category: Drugs & Pharmacology Authors: Jie Xu Aizhen Xiong Xunjiang Wang Xing Yan Yilin Chen Xuanling Ye Zhengtao Wang Lili Ding Li Yang Source Type: research
Corrigendum to "In vitro and in vivo antidiabetic activity, isolation of flavonoids, and in silico molecular docking of stem extract of Merremia tridentata (L.)" Biomed. Pharmacother. (2022) 112611
Biomed Pharmacother. 2023 Sep 19:115526. doi: 10.1016/j.biopha.2023.115526. Online ahead of print.NO ABSTRACTPMID:37734965 | DOI:10.1016/j.biopha.2023.115526
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: Lenh Vo Van Em Canh Pham Cuong Viet Nguyen Ngoc Thoi Nguyen Duong Tuong Vi Le Thi Tuyen Ngoc Truong Source Type: research
Pathophysiology of diabetic hepatopathy and molecular mechanisms underlying the hepatoprotective effects of phytochemicals
Biomed Pharmacother. 2023 Sep 19;167:115502. doi: 10.1016/j.biopha.2023.115502. Online ahead of print.ABSTRACTPatients with diabetes are at risk for liver disorders including glycogen hepatopathy, non-alcoholic fatty liver disease, cirrhosis, and hepatic fibrosis. The pathophysiological mechanisms behind diabetic hepatopathy are complex, some of them include fatty acid accumulation, increased reactive oxygen species, increased advanced glycation end-products, hyperactivity of polyol pathways, increased apoptosis and necrosis, and promotion of fibrosis. A growing number of studies have shown that herbal extracts and their a...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: Leila Mobasheri Mitra Ahadi Ali Beheshti Namdar Mohaddeseh Sadat Alavi Abolfazl Bemidinezhad Seyed Mostafa Moshirian Farahi Mahdi Esmaeilizadeh Niloofar Nikpasand Elham Einafshar Ahmad Ghorbani Source Type: research
Research progress on the pathogenesis of the SDHB mutation and related diseases
Biomed Pharmacother. 2023 Sep 19;167:115500. doi: 10.1016/j.biopha.2023.115500. Online ahead of print.ABSTRACTWith the improvement of genetic testing technology in diseases in recent years, researchers have a more detailed and clear understanding of the source of cancers. Succinate dehydrogenase B (SDHB), a mitochondrial gene, is related to the metabolic activities of cells and tissues throughout the body. The mutations of SDHB have been found in pheochromocytoma, paraganglioma and other cancers, and is proved to affect the occurrence and progress of those cancers due to the important structural functions. The importance o...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: Chang Liu Dayang Zhou Kexin Yang Ning Xu Jibang Peng Zhu Zhu Source Type: research
Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study
This article is protected by copyright. All rights reserved.PMID:37731282 | DOI:10.1002/jcph.2348
Source: The Journal of Clinical Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Ernesto Callegari Susanna Tse Angela C Doran Theunis C Goosen Naveed Shaik Source Type: research
Suppressive effect of Tripterygium hypoglaucum (Levl.) Hutch extract on rheumatoid arthritis in mice by modulating inflammasome and bile acid metabolism
In this study, we aimed to explore the critical role of NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and bile acid (BA) in the anti-RA mechanism. Complete Freund's adjuvant (CFA)-injected mice were treated with THH extract (250 mg/kg/d) for 35 days, and joint swelling and disease scores were measured. After THH treatment, the joint swelling and RA disease score in CFA-treated mice significantly subsided. The increased ratios of lymphocytes, monocytes, and white blood cells were attenuated by THH treatment. Notably, THH treatment blocked the inflammation in both joints and colons by suppressing the ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: Junping Zheng Jianghui Hu Yong Yang Lei Xiong Huabing Yang Zhigang Zhang Nan Jiang Hongtao Liu Source Type: research
Inhibition of xanthine oxidase-catalyzed xanthine and 6-mercaptopurine oxidation by luteolin, naringenin, myricetin, ampelopsin and their conjugated metabolites
In this study, we examined the impacts of luteolin, naringenin, myricetin, ampelopsin, and their sulfate/glucuronide derivatives on XO-catalyzed xanthine and 6-mercaptopurine oxidations employing in vitro enzyme incubation assays and molecular modeling studies. Our major results/conclusions are the following: (1) Sulfate metabolites were stronger while glucuronic acid derivatives were weaker inhibitors of XO compared to the parent flavonoids. (2) Naringenin, ampelopsin, and their metabolites were weak inhibitors of the enzyme. (3) Luteolin, myricetin, and their sulfates were highly potent inhibitors of XO, and the glucuron...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: Orsolya Bal ázs Ágnes Dombi Bal ázs Z Zsidó Csaba Het ényi Kate řina Valentová R óbert G Vida Mikl ós Poór Source Type: research
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer
This study explored the impact of genetic polymorphisms in ADME genes (responsible for drug absorption, distribution, metabolism, and elimination) on CDKis safety profiles in 230 patients. Selected endpoints include grade 3/4 neutropenia at day 14 of the first treatment cycle, early dose-limiting toxicities (DLTs), and dose reductions within the initial three cycles. Our analysis revealed associations between these endpoints and polymorphisms in CYP3A4, CYP3A5, ABCB1, and ABCG2 genes. Their impact on CDKis plasma concentrations (Ctrough) was also examined. Specifically, ABCB1 c.1236C>T and c.2677C>T polymorphisms cor...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: Elena Peruzzi Lorenzo Gerratana Marcella Montico Bianca Posocco Serena Corsetti Michele Bartoletti Sara Gagno Marco Orleni Elena De Mattia Massimo Baraldo Erika Cecchin Fabio Puglisi Giuseppe Toffoli Rossana Roncato Source Type: research
Role of toll-like receptor-mediated pyroptosis in sepsis-induced cardiomyopathy
Biomed Pharmacother. 2023 Sep 19;167:115493. doi: 10.1016/j.biopha.2023.115493. Online ahead of print.ABSTRACTSepsis, a life-threatening dysregulated status of the host response to infection, can cause multiorgan dysfunction and mortality. Sepsis places a heavy burden on the cardiovascular system due to the pathological imbalance of hyperinflammation and immune suppression. Myocardial injury and cardiac dysfunction caused by the aberrant host responses to pathogens can lead to cardiomyopathy, one of the most critical complications of sepsis. However, many questions about the specific mechanisms and characteristics of this ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: Yixuan Fan Baoyi Guan Jianxing Xu He Zhang Liang Yi Zhixu Yang Source Type: research
Therapeutic benefits of nitric oxide in lung transplantation
Biomed Pharmacother. 2023 Sep 19;167:115549. doi: 10.1016/j.biopha.2023.115549. Online ahead of print.ABSTRACTLung transplantation is an evolutionary procedure from its experimental origin in the twentieth century and is now recognized as an established and routine life-saving intervention for a variety of end-stage pulmonary diseases refractory to medical management. Despite the success and continuous refinement in lung transplantation techniques, the widespread application of this important life-saving intervention is severely hampered by poor allograft quality offered from donors-after-brain-death. This has necessitated...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: George J Dugbartey Source Type: research
Novel antidepressant mechanism of hypericin: Role of connexin 43-based gap junctions
Biomed Pharmacother. 2023 Sep 19;167:115545. doi: 10.1016/j.biopha.2023.115545. Online ahead of print.ABSTRACTHypericin is widely utilized for its precise antidepressant properties, but its exact antidepressant mechanism remains unclear. Gap junctions, which were predominantly expressed in astrocytes in the central nervous system, are concerned with the pathogenesis of depression. However, the role of hypericin in gap junctional dysfunction in depression has rarely been investigated. Here, we found that gap junctions were ultra-structurally broadened in the chronic unpredictable stress (CUS) rat model of depression, while ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 21, 2023 Category: Drugs & Pharmacology Authors: Huiqin Wang Xueying Yang Huaqing Lai Yang Sun Xu Yan Qidi Ai Meiyu Lin Songwei Yang Yantao Yang Shifeng Chu Zhenzhen Wang Naihong Chen Source Type: research
The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2
Curr Opin Pharmacol. 2023 Sep 19;73:102404. doi: 10.1016/j.coph.2023.102404. Online ahead of print.ABSTRACTInfectious agents such as human immune deficiency virus-1 (HIV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) use host proteins to infect, replicate, and induce inflammation within the host. A critical component of these diseases is the axis between pannexin-1 channels, extracellular ATP, and purinergic receptors. Here, we describe the potential therapeutic role of Pannexin-1/purinergic approaches to prevent or reduce the devastating consequences of these pathogens.PMID:37734241 | DOI:10.1016/j.coph.2023.102404
Source: Current Opinion in Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Cristian A Hernandez Eliseo A Eugenin Source Type: research
The MEK-ERK-Egr-1 axis and its regulation in cardiovascular disease
This article reviews recent progress on the MEK-ERK-Egr-1 cascade, notably regulation in conjunction with factors and agents such as TET2, TRIB2, MIAT, SphK1, cAMP, teneligliptin, cholinergic drugs, red wine and flavonoids, wogonin, febuxostat, docosahexaenoic acid and AT1R blockade. Such insights should provide new opportunity for therapeutic intervention in CVD.PMID:37734428 | DOI:10.1016/j.vph.2023.107232
Source: Vascular Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Levon M Khachigian Source Type: research
